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Introduction
============

The amyloid-β peptide (Aβ), a 39--43--amino acid cleavage product of amyloid precursor protein ([@bib23]; [@bib26]), has been implicated as the primary neurotoxic factor in Alzheimer\'s disease (AD) pathogenesis ([@bib79]). In vitro, Aβ is toxic to neurons ([@bib79]; [@bib8]; [@bib82]), endothelial cells ([@bib72]; [@bib33]), astrocytes ([@bib15]), vascular smooth muscle cells ([@bib39]; [@bib20]), and oligodendrocytes (OLGs; [@bib77]); and Aβ depositions in senile plaques are postulated to cause neuronal and vascular degeneration in AD brains ([@bib51]; [@bib79]; [@bib72]). Although Aβ-mediated cell death demonstrates morphological, biochemical, and molecular features of apoptosis, the molecular mechanism underlying Aβ cytotoxicity remains largely undefined but may involve oxidative stress ([@bib8]; [@bib60]). NF-κB and AP-1, redox-sensitive transcription factors, are activated in Aβ-treated OLGs, and *N*-acetylcysteine (NAC), an antioxidant, prevents Aβ-mediated OLG apoptosis ([@bib77]). OLGs are susceptible to oxidative stress because they have low levels of reduced glutathione (GSH) and high concentrations of iron, resulting in a compromised ability to scavenge peroxides ([@bib73]; [@bib5]; [@bib37]).

Ceramide, a lipid second messenger that increases the cellular oxidative state, has been implicated in several apoptosis paradigms including trophic factor withdrawal and exposure to proinflammatory molecules ([@bib19]; [@bib42]; [@bib41]). Cellular ceramide synthesis increases in response to stress or death signals ([@bib27]; [@bib70]; [@bib75]). One pathway of ceramide formation involves sphingomyelin hydrolysis by either neutral sphingomyelinase (nSMase) or acidic sphingomyelinase (aSMase; [@bib71]); both enzymes are involved in several cell death paradigms ([@bib41]; [@bib44]). Another pathway involves ceramide synthase--catalyzed de novo ceramide synthesis ([@bib12]; [@bib67]; [@bib76]).

Aβ and ceramide share cell death signaling characteristics. Aβ-induced apoptosis involves TNF-α, p75 neurotrophin receptor, and Fas ligand ([@bib10]; [@bib21]; [@bib78]), which are cell surface receptors that relay death signals through the sphingomyelin--ceramide pathway ([@bib22]; [@bib31]). Moreover, both Aβ ([@bib38]; [@bib4]; [@bib16]; [@bib77]) and ceramide ([@bib24]; [@bib65]) cause mitochondrial dysfunction and induce oxidative stress. In vitro, OLG death induced by Aβ ([@bib77]) or ceramide ([@bib43]; [@bib65]; [@bib62]) share similar apoptotic characteristics. Lower sphingomyelin levels and higher ceramide levels in AD brains have been reported ([@bib66]), thereby implying that increased sphingomyelin degradation and ceramide accumulation contribute to AD pathogenesis. We have previously shown that Aβ induced OLG death with characteristic features of apoptosis ([@bib77]). In this paper, we demonstrate that ceramide mediates Aβ-induced OLG death by activating the nSMase--ceramide cascade.

Results
=======

Aβ and C2-ceramide are cytotoxic to OLGs
----------------------------------------

We have previously shown that Aβ induced apoptosis in primary OLG cultures derived from neonatal rat brains, characterized by nuclear and cytoskeletal disintegration, DNA fragmentation, and mitochondrial dysfunction ([@bib77]). In this paper, we used neurosphere-derived differentiated OLGs because of their ease of preparation compared with primary OLG isolation. The neurosphere-derived differentiated OLGs exhibited characteristic OLG morphology, which is composed of large cell bodies with multiple branching processes ([Fig. 1](#fig1){ref-type="fig"}, A--H). Immunocytochemical analysis revealed that virtually all cells in culture expressed four OLG-specific surface markers including cyclic nucleotide 3′-phosphodiesterase ([Fig. 1](#fig1){ref-type="fig"} A, CNP), Rip ([Fig. 1](#fig1){ref-type="fig"} C), galactocerebroside ([Fig. 1](#fig1){ref-type="fig"} E, GalC), and PLP (myelin proteolipid protein; [Fig. 1](#fig1){ref-type="fig"} G). In addition, differentiated OLGs showed similar characteristic electrophysiological membrane potentials (unpublished data) as reported in previous studies ([@bib53]).

![**Characterization of OLG cultures.** Immunofluorescent (A, C, E, and G) and corresponding phase-contrast (B, D, F, and H) photomicrographs of neurosphere-derived differentiated OLGs in culture. Cells demonstrate characteristic morphology of OLGs, plump cell body with multiple branching processes. Virtually all cells in culture immunostained for the OLG-specific antigens, CNP (A), Rip (C), GalC (E), and PLP (G). Bar, 30 μm.](200307017f1){#fig1}

As demonstrated previously, Aβ 1-40 and Aβ 25-35 peptides have equal potencies for inducing death in primary cultures of OLGs ([@bib77]); thus, most of our studies were conducted using Aβ 25-35 with key experiments confirmed with Aβ 1-40. Aβ 25-35 treatment for 48 h caused OLG death in a concentration-dependent manner with an approximate EC~50~ = 20 μM ([Fig. 2](#fig2){ref-type="fig"} A). C2-ceramide, a cell-permeable ceramide analogue, also induced dose-dependent OLG death with an approximate EC~50~ = 30 μM ([Fig. 2](#fig2){ref-type="fig"} B). C2-dihydroceramide, a cell-impermeable and inactive form of ceramide, was not cytotoxic at concentrations up to 100 μM (unpublished data). The toxic effect of ceramide was apparent at an earlier time point than that of Aβ ([Fig. 3, A and B](#fig3){ref-type="fig"}), raising the possibility that ceramide may be a mediator of Aβ-induced cell death.

![**A**β **25-35 and C2-ceramide induced OLG death.** (A) OLGs treated with 10--100 μM Aβ 25-35 for 48 h. (B) OLGs exposed to 10--100 μM C2-ceramide for 24 h. The assessment of cell survival based on MTT assay or cell death based on LDH assay showed a dose-dependent cytotoxic effect of Aβ 25-35 and C2-ceramide. Data shown are representative of three separate experiments of triplicate samples with similar results; error bars represent SD.](200307017f2){#fig2}

![**Time-dependent cell death induced by A**β **25-35 and C2-ceramide.** (A) Cell survival as measured by MTT assay. (B) Cell death as determined by LDH assay. OLGs were treated with 20 μM Aβ 25-35 or 30 μM C2-ceramide for the time periods indicated. The cells and culture medium were used for the MTT or LDH assay, respectively. Note the faster pace of ceramide in inducing OLG death, 50% OLG death was noted 24 and 48 h after ceramide and Aβ treatment, respectively. Data shown are representative of three separate experiments of triplicate samples with similar results; error bars represent SD.](200307017f3){#fig3}

Ceramide in Aβ 25-35--induced OLG death
---------------------------------------

To support the contention that ceramide is involved in Aβ-induced OLG death, TLC and electrospray ionization/mass spectrometry (ESI/MS) were used to measure ceramide content in OLGs with and without Aβ treatment. Aβ 25-35 treatment resulted in a fivefold increase in ceramide synthesis as determined by TLC ([Fig. 4](#fig4){ref-type="fig"} A). An increase in cellular ceramide content was confirmed by ESI/MS, which demonstrated peak ceramide content 10 h after Aβ treatment ([Fig. 4](#fig4){ref-type="fig"} B). *N*-oleoyl-ethanolamine (NOE), a specific ceramidase inhibitor that prevents the degradation of cellular ceramide at subtoxic doses ([@bib68]; [@bib56]), augmented Aβ 25-35--induced OLG death ([Fig. 4](#fig4){ref-type="fig"} C). Together, these results suggest a strong correlation between increases in cellular ceramide levels and Aβ-induced OLG death.

![**A**β **25-35--induced ceramide production and enhancement of A**β **cytotoxicity by a ceramidase inhibitor.** (A) An increase in cellular ceramide synthesis in OLGs prelabeled with \[^3^H\]palmitate and treated with 10 μM Aβ 25-35 for 24 h. (B) Quantitative determination of endogenous ceramide concentration by ESI/MS at various time points after Aβ 25-35 treatment. Note the elevated ceramide content at 5, 10, and 16 h after Aβ 25-35 exposure. (C) Effect of NOE, a ceramidase inhibitor, on Aβ-induced OLG death. OLGs were treated with 10 μM Aβ 25-35 plus 1 μM NOE for 24 h. The culture medium was collected for the LDH assay. Data shown are mean ± SD of three separate experiments in triplicate. \*, Significant difference from control; \*\*, significant difference from Aβ treatment; P \< 0.05.](200307017f4){#fig4}

nSMase activation in Aβ 25-35--induced OLG death
------------------------------------------------

Ceramide is derived from sphingomyelin hydrolysis catalyzed by nSMase or aSMase ([@bib31]). Aβ 25-35 treatment increased nSMase activity in OLGs as early as 2.5 min after exposure and reached maximal levels at ∼16 h ([Fig. 5](#fig5){ref-type="fig"} A). Aβ 1-40 treatment also increased OLG nSMase activity in a similar manner (unpublished data). In contrast, Aβ 25-35 treatment did not alter aSMase activity ([Fig. 5](#fig5){ref-type="fig"} A). The addition of recombinant bacterial sphingomyelinase (bSMase), an exogenous source of sphingomylinase that mimics nSMase action by degrading membrane sphingomyelin to increase cellular ceramide levels ([@bib55]; [@bib36]; [@bib83]; [@bib74]), caused OLG death ([Fig. 5](#fig5){ref-type="fig"} B). Furthermore, the nSMase inhibitors, 3-*O*-methyl-sphingomyelin (3-OMe-SM; [@bib45]) and NAC ([@bib47]; [@bib81]), were effective in protecting OLGs against Aβ cytotoxicity ([Fig. 5, C and D](#fig5){ref-type="fig"}). Confirming the effects of the nSMase inhibitors, a marked reduction in nSMase enzymatic activity was observed in OLGs treated with 3-OMe-SM or NAC ([Fig. 6](#fig6){ref-type="fig"} A). Moreover, significant decreases in endogenous ceramide content and increases in sphingomyelin levels were detected in OLGs treated with the inhibitors ([Fig. 6, B and C](#fig6){ref-type="fig"}). To further confirm the contribution of nSMase in Aβ-mediated cell death, sense and antisense oligonucleotides specific for nSMase were generated. Antisense oligonucleotides reduced nSMase activity ([Fig. 7](#fig7){ref-type="fig"} A), reduced ceramide content in cell lysates ([Fig. 7](#fig7){ref-type="fig"} B), and attenuated Aβ-induced cell death ([Fig. 7](#fig7){ref-type="fig"} C), but sense oligonucleotides had no effect on nSMase activity, ceramide content, or cell survival.

![**Sphingomyelinase in A**β**-induced OLG death.** (A) nSMase and aSMase activity in OLGs treated with 10 μM Aβ 25-35 for various time periods (from 2.5 min to 36 h). (B) Aβ or bSMase induced OLG death as determined by LDH assay. OLGs were exposed to 10 μM Aβ 25-35 or bSMase (1 U/ml) for 24 h. (C) LDH and (D) trypan blue assays on the effects of nSMase inhibitors on Aβ-mediated OLG death. OLGs were treated with 25 mM NAC or 1 μM 3-OMe-SM for 2 h before 10 μM Aβ 25-35 treatment for 24 h. Data shown are representative of three separate experiments of triplicate samples with similar results; error bars represent SD. \*, Significant difference from control; \*\*, significant difference from Aβ treatment; P \< 0.05.](200307017f5){#fig5}

![**Effect of nSMase inhibitors on sphingomyelinase activity and ceramide/sphingomyelin content in A**β **25-35--treated OLGs.** nSMase and aSMase activity (A) and cellular ceramide (B) and sphingomyelin (C) content in OLGs treated with NAC or 3-OMe-SM nSMase inhibitors. OLGs were treated with 1 μM 3-OMe-SM or 25 mM NAC for 2 h before 10 μM Aβ 25-35 exposure for 16 h. Representative TLC data are shown from one of three experiments in the top panels in B and C. A and the bottom panels in B and C show composite results from three separate experiments; error bars represent SD. \*, Significant difference from control; \*\*, significant difference from Aβ treatment; P \< 0.05.](200307017f6){#fig6}

![**Treatment of OLGs with nSMase antisense oligonucleotides.** OLGs were treated with sense or antisense oligonucleotides specific for nSMase 4 h before 20 μM Aβ addition. After 24 h, the cells were harvested and assayed for nSMase activity (A), ceramide content (B), and MTT (C). The graph depicts a representative of three separate experiments with similar results; error bars represent SD. \*, Significant differences compared with Aβ treatment alone; P \< 0.05.](200307017f7){#fig7}

It has been shown that Aβ depletes GSH in cortical neurons in vitro ([@bib54]), which correlates well with the ability of Aβ to heighten cellular oxidative stress ([@bib18]). GSH depletion has been shown to activate nSMase activity ([@bib46]; [@bib47],[@bib48]). The fact that NAC, a GSH precursor, inhibited Aβ 25-35 activation of nSMase and prevented Aβ-mediated OLG death suggests that Aβ 25-35 depletion of cellular GSH is involved in the Aβ--nSMase--ceramide OLG death signaling cascade. Buthionine sulfoximine (BSO) and diethyl maleate (DEM) have been shown to deplete GSH in various cell types ([@bib3]; [@bib52]; [@bib69]). Both BSO and DEM selectively increased nSMase activity ([Fig. 8](#fig8){ref-type="fig"} A), increased ceramide levels ([Fig. 8](#fig8){ref-type="fig"} B), decreased cellular GSH levels ([Fig. 8](#fig8){ref-type="fig"} C), and were cytotoxic to OLGs ([Fig. 8](#fig8){ref-type="fig"} D).

![**Effects of GSH depleting agents compared with A**β **25-35 on sphingomyelinase activity, cellular GSH content, and cell survival.** OLGs were treated with 10 μM Aβ 25-35, 100 μM BSO, or 500 μM DEM for 16 h before measurement of sphingomyelinase activity (A), ceramide synthesis (B), or GSH content (C), or 24 h before MTT assay (D). Data shown in A, C, and D are representative of three separate experiments of triplicate samples and, in B, of two separate experiments with similar findings; error bars represent SD. \*, Significant difference from control; P \< 0.05.](200307017f8){#fig8}

Because Aβ 25-35 did not activate aSMase, it is unlikely that aSMase is involved in Aβ 25-35--induced OLG death. Selective aSMase inhibitors such as desipramine and chlorpromazine ([@bib2]) were ineffective in protecting OLGs from Aβ 25-35--induced death (unpublished data). Furthermore, fumonisin B~2~, a ceramide synthase inhibitor, did not block Aβ 25-35 cytotoxicity in this cell death paradigm (unpublished data). Together, these results suggest that ceramide generation catalyzed by nSMase, but not aSMase or ceramide synthase, mediates the Aβ 25-35 death pathway in OLGs.

Discussion
==========

Several lines of evidence support the contention that ceramide mediates, at least in part, Aβ-induced OLG death. Both Aβ and C2-ceramide (but not the biologically inactive dihydroceramide) caused OLG death in a time-dependent manner. Aβ treatment increased ceramide formation in OLGs. In addition, increasing cellular ceramide release from sphingomyelin by exogenous bSMase, which mimics cellular nSMase action, also induced OLG death. Inhibition of ceramide degradation by NOE, a ceramidase inhibitor, enhanced Aβ cytotoxicity in OLGs.

Results from this study also support the contention that Aβ cytotoxicity is mediated via activation of nSMase leading to increased cellular ceramide generation. Aβ 25-35 and Aβ 1-40 activated nSMase, but not aSMase, in OLGs. Additionally, nSMase inhibitors such as 3-OMe-SM and NAC (also an antioxidant) prevented Aβ 25-35--induced nSMase activity, which resulted in decreased ceramide synthesis from sphingomyelin and protected OLGs from Aβ 25-35 cytotoxicity. Antisense oligonucleotides specific for nSMase also attenuated Aβ-induced OLG cell death, further implicating nSMase as a mediator. Chemical agents such as BSO and DEM that deplete cellular GSH content also activated nSMase in OLGs and caused cell death. The specific role of nSMase in Aβ-induced OLG death is supported by the finding that pharmacological inhibition of nSMase, but not aSMase or ceramide synthase, prevented Aβ 25-35--induced OLG death.

The exact mechanism underlying Aβ-mediated nSMase activation remains to be elucidated but may involve changes in the cellular redox state and/or GSH metabolism ([@bib59]); GSH is the most abundant thiol-containing compound in living cells. nSMase enzymatic activity is directly regulated by cellular GSH content ([@bib46]; [@bib47],[@bib48]). Aβ has been shown to deplete GSH in cultured cortical neurons ([@bib54]), and depletion of cellular GSH stores by oxidative stress has been proposed as a prime mechanism underlying the Aβ cytotoxic action ([@bib54]; [@bib57]). Thus, it is plausible that a decrease in GSH level subsequent to Aβ exposure may activate nSMase in OLGs. NAC, a GSH precursor, inhibited Aβ 25-35 activation of nSMase and protected OLGs against Aβ-induced death, whereas depletion of cellular GSH stores by BSO or DEM resulted in selective activation of nSMase and OLG death. Although the agents used to manipulate GSH levels may be relatively nonspecific, these findings raise the possibility that the activation of nSMase by Aβ may involve the depletion of cellular GSH content.

Oxidative stress plays a prominent role in Aβ-mediated neuronal and OLG death ([@bib8]; [@bib6]; [@bib50]; [@bib77]). Brain tissue is especially sensitive to oxidative injury because of its higher metabolic rate driven by glucose, lower concentrations of protective antioxidants, and higher levels of polyunsaturated fatty acids that are susceptible to lipid peroxidation ([@bib7]; [@bib6]; [@bib50]). Although Aβ-mediated oxidative stress induces mtDNA damage ([@bib13]; [@bib77]) and activates selected transcription factors including NF-κB and AP-1 ([@bib1]; [@bib61]; [@bib58]; [@bib77]), the mechanism by which Aβ induces oxidative stress in the AD brain remains unknown. Ceramide has emerged as a potent second messenger in oxidative stress-induced apoptosis ([@bib32]). Hydrogen peroxide ([@bib25]), 1-β-[d]{.smallcaps}-arabinofuranosylcytosine ([@bib14]), daunorubicin ([@bib34]), TNF-α ([@bib9]), γ-rays ([@bib17]), hypoxia ([@bib80]), CD40 activation ([@bib63]), and sindbis virus infection ([@bib35]) are among the agents that can mediate cell death via nSMase activation, thus emphasizing the central role of the nSMase--ceramide cascade. Results shown here provide a unique signaling pathway from cell surface Aβ engagement, induction of oxidative stress, and activation of the nSMase--ceramide cascade culminating in OLG death.

In summary, this work demonstrates a novel mechanism for Aβ-induced OLG death. These results reveal a causal relationship between Aβ exposure and the activation of the nSMase--ceramide pathway, which is likely to involve heightened oxidative stress after depletion of cellular GSH stores. In addition, we have evidence that activation of the nSMase--ceramide cascade may also contribute to Aβ-induced death of cortical neurons and cerebral endothelial cells (unpublished data), thereby suggesting that this cascade may be operating in many cell types other than OLGs. Aβ→nSMase→ceramide cascade represents a novel signaling pathway that contributes at least in part to Aβ cytotoxicity to various types of brain cells. Identification of this pathway may lead to the development of more effective therapeutic strategies aimed at preventing Aβ-induced cell death. For instance, blockade of the Aβ-activated death signaling process can be achieved by pharmacological modulation of nSMase activity as demonstrated in this work.

Materials and methods
=====================

Reagents and cell culture
-------------------------

All chemicals were purchased from Sigma-Aldrich, and all cell culture reagents were purchased from Invitrogen unless otherwise specified. B104 cells (a gift from David Schubert, Salk Institute for Biological Studies, La Jolla, CA) were cultured in DME supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.

OLG culture
-----------

Neurospheres were cultured using the methods of [@bib84] with modifications. In brief, embryonic rat brains (E14--16 d) were dissected, homogenized gently in DME/Ham\'s F12, and centrifuged at 350 *g* for 5 min. The pellet was digested with 0.05% trypsin in 1.5 ml of 0.53 M EDTA for 30 min at 37°C, followed by the addition of 1.5 ml DME/Ham\'s F12 with 20% FBS, and filtered through 10-μm nylon mesh. The filtrate was centrifuged at 350 *g* for 5 min, and the pellet was washed twice with DME/Ham\'s F12. Dissociated cells were layered on a preequilibrated Percoll gradient (formed by centrifuging 50% Percoll and 50% DME/Ham\'s F12 at 23,500 *g* for 1 h at 4°C) and centrifuged at 3,500 *g* for 15 min. The fraction containing glial progenitors banding between myelin and blood cell layers was recovered and washed twice with DME/Ham\'s F12 followed by another wash with neurosphere culture medium (DME/Ham\'s F12/Hepes, N1 supplement, 25 μg/ml insulin, 130 ng/ml progesterone, 20 ng/ml of basic FGF, and 20 ng/ml EGF). The cell pellet was resuspended in 20 ml of neurosphere culture medium and seeded in 75-mm culture flasks. After 24 h, when neurospheres had formed, 5 ml of fresh medium was added to each culture every other day for 7 d, and then the neurosphere cultures were split (1:2). The neurospheres were dissociated gently 10 times with a syringe and a 25-gauge needle and centrifuged at 350 *g*. The resulting cell pellets were treated with 0.05% trypsin/0.53 mM EDTA and centrifuged at 350 *g* for 10 min. The cells were resuspended in progenitor medium (69% DME/Ham\'s F12/Hepes containing N1 supplement, 10 μg/ml insulin, 20 nM progesterone, 30% conditioned medium from B104 cells, and 1% FBS) and plated on 100-mm culture dishes precoated with poly-[l]{.smallcaps}-ornithine. For differentiated OLG cultures, progenitor cells were detached with trypsin/EDTA and cultured on poly-[l]{.smallcaps}-ornithine--coated plates or coverslips in mature OLG medium (DME/Ham\'s F12; N1 supplement, 20 μg/ml biotin; 20 μg/ml triiodo-[l]{.smallcaps}-thyronine, T3, and 1% FBS).

Immunocytochemistry
-------------------

Differentiated OLG cultures were fixed in 4% PFA, washed in PBS, and blocked with 5% goat serum. Fixed cells were incubated with the primary antibody overnight at 4°C. The following primary antibodies were used: anti--mouse CNP, anti--mouse Rip, anti--mouse PLP (Chemicon), and anti--mouse GalC (Cedarlane Laboratories) at a concentration of 1:100. The secondary antibody, anti--mouse IgG conjugated to FITC (Vector Laboratories), was added for 1 h at RT. The cells were washed in PBS and visualized using a confocal microscope (model LSM 5 Pascal; Carl Zeiss MicroImaging, Inc.) equipped with a CCD camera (model Axiocam HR; Carl Zeiss MicroImaging, Inc.). Images were collected and processed using Adobe Photoshop software.

Sphingomyelinase assay
----------------------

The cells were washed twice with PBS, pH 7.4, and lysed in 0.2% Triton X-100 for 10 min at 4°C. The lysates were sonicated for 30 s in ice-cold bath, and protein concentrations were determined by Lowry assay ([@bib49]). A sphingomyelinase substrate, \[methyl-^14^C\]sphingomyelin (55 mCi/mmol; Amersham Biosciences), was evaporated to dryness and resuspended in either 25 μl of nSMase assay buffer (40 mM Hepes, 5 mM MgCl~2~, and 0.2% Triton X-100, pH 7.4) or aSMase assay buffer (250 mM sodium acetate and 0.2% Triton X-100, pH 5.2) and sonicated to form micelles on ice until use. Each reaction containing 25 μl of cell lysate protein (1 mg/ml) and 25 μl \[methyl-^14^C\]sphingomyelin (0.23 nmol) in nSMase or aSMase assay buffer was incubated for 2 h at 37°C. The reaction was terminated with 200 μl CHCl~3~/methanol (1:1) and 90 μl H~2~O followed by vigorous agitation. The samples were centrifuged at 6,000 *g* for 5 min. \[^14^C\]Phosphocholine in the aqueous phase (120 μl) was collected for liquid scintillation counting. Phosphocholine is the degraded moiety of sphingomyelin after ceramide is released by nSMase or aSMase. The aSMase or nSMase activity was calculated as picomoles of sphingomyelin hydrolyzed by 1 mg of total proteins per hour and expressed as a percentage of control values.

TLC
---

OLGs with or without Aβ 25-35 treatment were cultured with 10 μCi \[^3^H\]palmitate (1 mCi/ml; Amersham Biosciences; [@bib38]). The labeled cells were collected and washed twice with PBS, pH 7.4, to remove free isotope before lipid extraction ([@bib76]). The cell pellet was resuspended in 400 μl methanol/1 N HCl (100:6, vol/vol) followed by 800 μl chloroform and 240 μl H~2~O. The sample was mixed and centrifuged at 6,000 *g* for 5 min. The lipid fraction was reextracted with 1 ml chloroform/methanol (2:1, vol/vol) and applied to a TLC plate. The solvent was chloroform/methanol/acetic acid/H~2~O (85:4.5:5:0.5, vol/vol) for ceramide and chloroform/methanol/acetic acid/water (65:25:8.8:4.5, vol/vol) for sphingomyelin. Plates were air dried and sprayed with 1 M sodium salicylate for autoradiography. Standard lipids were stained by rhodamine 6G (Sigma-Aldrich) and visualized by UV light.

Quantitative ceramide analysis by ESI/MS
----------------------------------------

After three washes with PBS, pH 7.4, OLGs harvested from 100-mm culture plates with or without Aβ 25-35 treatment were homogenized in 0.5 ml PBS, pH 7.4, with a glass tissue grinder. A bicinchomic protein assay kit was used to determine the protein concentration before lipid extraction (Pierce Chemical Co.). Lipids from the homogenates were extracted as described previously with modifications ([@bib11]) using 50 mM LiOH in the aqueous layer and C17:0 ceramide (2 nmol/mg protein) as an internal standard for quantitation of ceramide content. These molecular species represent \<1% of the endogenous cellular lipid mass. The lipid extracts were dried under a nitrogen stream, dissolved in chloroform, desalted with Sep-Pak columns, and filtered with 0.2 μm PTFE syringe filters (Fisher Scientific). Lipids were reextracted with 20 mM LiOH in the aqueous layer, dried under a nitrogen stream, and resuspended in 0.5 ml of chloroform/methanol (1:1, vol/vol) for ESI/MS analysis.

ESI/MS analysis was performed using a spectrometer (model TSQ-7000; Finnigan) equipped with an electrospray ion source as described previously ([@bib29], [@bib30]). A 5-min period of signal averaging in the profile mode was used for each spectrum of a lipid extract. All extracts were directly infused into the ESI chamber using a syringe pump at 1 μl/min flow rate. Ceramide in the lipid extracts was quantitated directly as deprotenated ions (\[M-H\]^−^) in comparison with an internal standard (C17:0 ceramide) after correction for ^13^C isotope effects in the negative-ion mode. Ion peaks were identified using tandem mass spectroscopic analyses as described previously ([@bib28]).

Cell death assays
-----------------

OLG viability was quantitated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue exclusion method. Cell death was also assessed by the amount of lactate dehydrogenase (LDH) release into the culture medium after Aβ or C2-ceramide treatment ([@bib40]; [@bib64]; [@bib76]). The amount of LDH released by cells killed with Triton X-100 was considered maximal cell death or "full kill" ([@bib76]).

Assay for cellular GSH content
------------------------------

Cellular GSH levels were determined using a GSH-400 colorimetric assay kit (Calbiochem-Novabiochem). Triplicate samples (3 × 10^6^ cells) were collected by centrifugation and washed twice with PBS, pH 7.4. The cell pellets were treated with 5% metaphosphoric acid (Sigma-Aldrich). A Teflon pestle was used to homogenize the cells. Protein concentrations were determined by Lowry assay ([@bib49]). The homogenates were centrifuged at 3,000 *g* for 10 min at 4°C. Supernatants were assayed for GSH according to the instructions provided with the kit. A standard curve was generated with graded concentrations of GSH (5--40 μM). GSH concentration was measured by absorbance at 400 nm with a spectrophotometer.

nSMase antisense oligonucleotides
---------------------------------

Morpholino sense (GCCGCAGAGAAAAGTTGTGCTTCAT) and antisense (CCTCTTACCTCAGTTACAATTTATA) oligonucleotides were generated for nSMase (Gene Tools, LLC). OLGs in serum-free medium were treated with 1.4 μM oligonucleotides in EPEI delivery solution (per manufacturer\'s instructions; Gene Tools) for 4 h. The medium was exchanged and Aβ was added for 24 h, after which cells were harvested for nSMase activity or cell death determination.

Statistical analysis
--------------------

Results are expressed as mean ± SD. Differences among groups were analyzed by one-way ANOVA followed by Bonferroni\'s post-hoc *t* test to determine statistical significance. Comparison between two experimental groups was based on two-tailed *t* test. P \< 0.05 was considered statistically significant.
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